肺癌组织中P53和ras-P21癌基因蛋白的免疫组织化学研究  

Immunohistochemical study on expression of P53 and ras-P21 oncoproteins in lung cancer

作　　者：李允模[1] 尹香花[1] 安昌善[1] 吴今子[1] 金河凤[1] 

机构地区：[1]延边大学医学院附属医院,延吉133000

出　　处：《吉林医学院学报》1999年第1期34-36,共3页

摘　　要：目的：为探讨肺癌组织中Ｐ＾５３和Ｐ６２１癌基因蛋白的表达及其临床意义。方法：应用免疫组化方法检测６９例肺癌组织标本中Ｐ＾５３和Ｐ＾２１癌基因蛋表达，结果采用卡方检验。结果：Ｐ＾５３和Ｐ＾２１在肺癌组织中的阳性表达率分别为４９．３％，６８．１％；肺癌癌旁支气管粘膜和腺体中的生表达率分别为０和１７．６％，与肿瘤区相比比较差异均非常显著。Objective: To determine the correlation between P53.P21 expression and its clinical significance. Methods:Immunohistochemical method (S - P method) were used to study the expression of P53 and P21 in 69 cases of lung cancer. The results tested by using chisguare test. Result: The positve rate of P53 and P21 oncoproteins in lung cancer were 49. 3 %,68. 1 % respetively; and that in tissues surrounding the cancer were o and 17. 6% respectively. Comparing with the positive rate of section of tumor and section of surrounding the discrepancies were very obvious (P <0.01). There was statistically significant correlation between the level of expression of P53 proteins and patient survival. The expression of P21 position were related to the type of histology. P21 expression was overexpressed in the adenocarcinomas as compared to the squamous cell carcinomas (P < 0 .05). No correlation was found between expression of P53 P21 and sex, age, differentiated or clinical tumor stage. Conclusion: Our data indicated that in lung cancer the level of expression of P53 does significantly affect the length of patient survival and is therefore at present of use as one of diagnostic indicator for this disease. Mutation of the ras oncogene is an early event in lung cancer.

关 键 词：肺癌 癌基因产物 P53 ras-P^21 免疫组化 

分 类 号：R734.202[医药卫生—肿瘤]